知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.015 seconds)

    Methods for suppressing acute rejection of a heart transplant
    1.
    发明授权
    Methods for suppressing acute rejection of a heart transplant 有权
    抑制心脏移植急性排斥反应的方法

    公开(公告)号：US08623355B2

    公开(公告)日：2014-01-07

    申请号：US12085065

    申请日：2006-11-15

    Applicant: Masaji Okada ,  Masafumi Takahashi ,  Atsushi Izawa ,  Yoshiyuki Ohsugi ,  Masahiko Mihara

    Inventor： Masaji Okada ,  Masafumi Takahashi ,  Atsushi Izawa ,  Yoshiyuki Ohsugi ,  Masahiko Mihara

    IPC: A61K39/395 ,  C07K16/00 ,  C07K16/28 ,  A61P37/06

    CPC classification number: C07K16/248 ,  A61K2039/505 ,  C07K16/2866

    Abstract: The effect of anti-IL-6 receptor antibodies in suppressing cytotoxic T cell induction was examined. The results showed that CTL activity against alloantigens was statistically significantly reduced in mice treated with anti-IL-6 receptor antibodies as compared to mice not treated with antibodies and mice treated with a control antibody. The anti-IL-6 receptor antibody was also administered to recipients of a mouse model for allogenic heart transplantation. As a result, histopathological findings showed that inflammatory cell infiltration into transplanted hearts was suppressed and the survival period of transplanted hearts was significantly prolonged. Thus, the present inventors for the first time discovered that administration of anti-IL-6 receptor antibodies could suppress cytotoxic T cell induction and thereby suppress acute rejection after transplantation.

    Abstract translation: 检测抗IL-6受体抗体在抑制细胞毒T细胞诱导中的作用。 结果表明，与未用抗体治疗的小鼠相比，用对照抗体处理的小鼠相比，用抗IL-6受体抗体处理的小鼠中，抗同种异体抗体的CTL活性显着降低。 还将抗IL-6受体抗体施用于用于同种异体心脏移植的小鼠模型的受体。 结果，组织病理学检查结果显示，移植心脏的炎症细胞浸润被抑制，移植心脏的存活期显着延长。 因此，本发明人首次发现，抗IL-6受体抗体的施用可以抑制细胞毒性T细胞诱导，从而抑制移植后的急性排斥反应。

    Pyridine derivatives and their use as anti-allergic agents
    2.
    发明授权
    Pyridine derivatives and their use as anti-allergic agents 失效
    吡啶衍生物及其作为抗过敏剂的用途

    公开(公告)号：US4691018A

    公开(公告)日：1987-09-01

    申请号：US860211

    申请日：1986-05-06

    Applicant: Takashi Mori ,  Nobuhiro Ohi ,  Yoshiyuki Ohsugi ,  Yasuhiro Yamashita

    Inventor： Takashi Mori ,  Nobuhiro Ohi ,  Yoshiyuki Ohsugi ,  Yasuhiro Yamashita

    IPC: C07D213/55 ,  A61K31/44 ,  A61K31/4425 ,  A61K31/455 ,  A61P37/06 ,  A61P37/08 ,  C07D213/56 ,  C07D213/81 ,  C07D213/60

    CPC classification number: C07D213/81

    Abstract: A compound of the formula ##STR1## wherein R.sub.1 is a hydrogen atom or a lower alkyl group which may be substituted with hydroxy, lower alkyl or di-lower alkylamino; R.sub.2 is a hydrogen atom, an amino group or a lower alkylamino group; and R.sub.3 is a lower alkyl group, and a non-toxic salt thereof, and a process for preparing the same are disclosed.The compound and the salts thereof exhibit anti-allergic effects by the two different mechanisms and are expected to be useful as drugs for treating allergic diseases such as asthma, pollen allergy, atopic dermatitis and the like.

    Abstract translation: 式IMA化合物，其中R 1为氢原子或可被羟基，低级烷基或二低级烷基氨基取代的低级烷基; R2是氢原子，氨基或低级烷基氨基; 和R3为低级烷基，及其无毒盐及其制备方法。 化合物及其盐表现出两种不同机理的抗过敏作用，并且预期可用作治疗过敏性疾病如哮喘，花粉过敏，特应性皮炎等的药物。

    Agents for Suppressing the Induction of Cytotoxic T Cells
    3.
    发明申请
    Agents for Suppressing the Induction of Cytotoxic T Cells 有权
    抑制细胞毒性T细胞诱导剂

    公开(公告)号：US20090263384A1

    公开(公告)日：2009-10-22

    申请号：US12085065

    申请日：2006-11-15

    Applicant: Masaji Okada ,  Masafumi Takahashi ,  Atsushi Izawa ,  Yoshiyuki Ohsugi ,  Masahiko Mihara

    Inventor： Masaji Okada ,  Masafumi Takahashi ,  Atsushi Izawa ,  Yoshiyuki Ohsugi ,  Masahiko Mihara

    IPC: A61K39/395 ,  A61P37/06

    CPC classification number: C07K16/248 ,  A61K2039/505 ,  C07K16/2866

    Abstract: The effect of anti-IL-6 receptor antibodies in suppressing cytotoxic T cell induction was examined. The results showed that CTL activity against alloantigens was statistically significantly reduced in mice treated with anti-IL-6 receptor antibodies as compared to mice not treated with antibodies and mice treated with a control antibody. The anti-IL-6 receptor antibody was also administered to recipients of a mouse model for allogenic heart transplantation. As a result, histopathological findings showed that inflammatory cell infiltration into transplanted hearts was suppressed and the survival period of transplanted hearts was significantly prolonged. Thus, the present inventors for the first time discovered that administration of anti-IL-6 receptor antibodies could suppress cytotoxic T cell induction and thereby suppress acute rejection after transplantation.

    Abstract translation: 检测抗IL-6受体抗体在抑制细胞毒T细胞诱导中的作用。 结果表明，与未用抗体治疗的小鼠相比，用对照抗体处理的小鼠相比，用抗IL-6受体抗体处理的小鼠中，抗同种异体抗体的CTL活性显着降低。 还将抗IL-6受体抗体施用于用于同种异体心脏移植的小鼠模型的受体。 结果，组织病理学检查结果显示，移植心脏的炎症细胞浸润被抑制，移植心脏的存活期显着延长。 因此，本发明人首次发现，抗IL-6受体抗体的施用可以抑制细胞毒性T细胞诱导，从而抑制移植后的急性排斥反应。

    Novel anitsense oligonucleotide derivatives against to hepatitis c virus
    10.
    发明申请
    Novel anitsense oligonucleotide derivatives against to hepatitis c virus 审中-公开
    针对丙型肝炎病毒的新型琥珀酸寡核苷酸衍生物

    公开(公告)号：US20050059617A1

    公开(公告)日：2005-03-17

    申请号：US10489771

    申请日：2002-09-17

    Applicant: Takeshi Imanishi ,  Satoshi Obika ,  Yoshiyuki Ohsugi

    Inventor： Takeshi Imanishi ,  Satoshi Obika ,  Yoshiyuki Ohsugi

    IPC: A61K31/14 ,  A61K31/712 ,  A61K38/00 ,  A61P31/14 ,  C07H21/00 ,  C12N15/113 ,  A61K48/00 ,  C07H21/02

    CPC classification number: C07H21/00 ,  A61K31/712 ,  A61K38/00 ,  C12N15/1131 ,  C12N2310/11 ,  C12N2310/3231

    Abstract: An antisense oligonucleotide derivative against HCV is provided which contains one or more nucleotide analogue units having a modified sugar portion and represented by the following general formula where B denotes a pyrimidine or purine nucleic acid base or an analogue thereof. The derivative of the present invention is an antisense against hepatitis C virus (HCV) gene, binds to HCV-RNA with high affinity within cells, can control and inhibit the expression of its gene with high efficiency, and shows high resistance to nucleases. The BNA antisense oligonucleotide of the present invention is also effective in an antisense method targeting HCV, no matter what secondary structures, such as loops or stems, in a target RNA nucleic acid are.

    Abstract translation: 提供了针对HCV的反义寡核苷酸衍生物，其含有一个或多个具有修饰的糖部分的核苷酸类似物单元，并由以下通式表示，其中B表示嘧啶或嘌呤核酸碱基或其类似物。 本发明的衍生物是针对丙型肝炎病毒（HCV）基因的反义，与细胞内高亲和力的HCV-RNA结合，可以高效控制和抑制其基因的表达，并显示出对核酸酶的高抗性。 本发明的BNA反义寡核苷酸在靶向HCV的反义方法中也是有效的，无论靶RNA核酸中的二级结构如环或茎如何。

Patent Agency Ranking